Ublituximab: Difference between revisions
Content deleted Content added
m →top: infobox |
+ cites |
||
| Line 51: | Line 51: | ||
It is in [[phases of clinical research|Phase 3 clinical trials]] for [[multiple sclerosis]].<ref>{{ClinicalTrialsGov|NCT03277261|A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 1)}}</ref> |
It is in [[phases of clinical research|Phase 3 clinical trials]] for [[multiple sclerosis]].<ref>{{ClinicalTrialsGov|NCT03277261|A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 1)}}</ref> |
||
It is also in "U2" Phase 3 clinical trials for [[chronic lymphocytic leukemia]] in combination with [[Umbralisib]].<ref>{{cite journal | vauthors = Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, Schreeder MT, Siddiqi T, Flowers CR, Cohen JB, Sportelli P, Miskin HP, Weiss MS, O'Brien S | display-authors = 6 | title = Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia | journal = Blood | volume = 134 | issue = 21 | pages = 1811–1820 | date = November 2019 | pmid = 31558467 | pmc = 7042665 | doi = 10.1182/blood.2019002118 }}</ref><ref>{{cite journal | vauthors = Babiker HM, Glode AE, Cooke LS, Mahadevan D | title = Ublituximab for the treatment of CD20 positive B-cell malignancies | journal = Expert Opinion on Investigational Drugs | volume = 27 | issue = 4 | pages = 407–412 | date = April 2018 | pmid = 29609506 | doi = 10.1080/13543784.2018.1459560 }}</ref> |
|||
It is also in "U2" Phase 3 clinical trials for [[chronic lymphocytic leukemia]] in combination with Umbralisib. |
|||
==See also== |
==See also== |
||
Revision as of 15:46, 19 December 2021
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | CD20 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Ublituximab is an immunomodulator. It binds to CD20.[1]
It is in Phase 3 clinical trials for multiple sclerosis.[2]
It is also in "U2" Phase 3 clinical trials for chronic lymphocytic leukemia in combination with Umbralisib.[3][4]
See also
References
- ^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4).
- ^ Clinical trial number NCT03277261 for "A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 1)" at ClinicalTrials.gov
- ^ Lunning M, Vose J, Nastoupil L, Fowler N, Burger JA, Wierda WG, et al. (November 2019). "Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia". Blood. 134 (21): 1811–1820. doi:10.1182/blood.2019002118. PMC 7042665. PMID 31558467.
- ^ Babiker HM, Glode AE, Cooke LS, Mahadevan D (April 2018). "Ublituximab for the treatment of CD20 positive B-cell malignancies". Expert Opinion on Investigational Drugs. 27 (4): 407–412. doi:10.1080/13543784.2018.1459560. PMID 29609506.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |